Dongwha Pharm.Co.,Ltd (KRX:000020)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,090.00
-110.00 (-2.12%)
At close: Aug 21, 2026

Dongwha Pharm.Co.,Ltd Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
513,242496,394464,875361,109340,426293,018
Other Revenue
-----0-
513,242496,394464,875361,109340,426293,018
Revenue Growth
6.59%6.78%28.73%6.08%16.18%7.70%
Cost of Revenue
287,006277,847250,617170,693159,436143,671
Gross Profit
226,236218,547214,258190,416180,990149,347
Selling, General & Admin
167,189176,639165,146142,338125,515103,217
Research & Development
25,33025,70123,59921,54819,28517,338
Amortization of Goodwill & Intangibles
3,4673,4042,9761,1391,3271,491
Other Operating Expenses
1,2572,4072,3622,2911,9931,808
Operating Expenses
207,844218,791200,847171,750151,075126,848
Operating Income
18,392-243.2513,41118,66629,91522,499
Interest Expense
-5,645-4,513-2,152-308.01-370-383.11
Interest & Investment Income
2,2062,0452,4916,6832,4931,744
Earnings From Equity Investments
156.08--219.372,420-2,269-410.4
Currency Exchange Gain (Loss)
-687.5-27.28-460.25377.7831.87687.36
Other Non Operating Income (Expenses)
2,279-577.91566.8145.65527.55630.9
EBT Excluding Unusual Items
16,700-3,31713,63727,98530,32824,768
Gain (Loss) on Sale of Investments
-4,727454.76-6,4359,434-4,5061,801
Gain (Loss) on Sale of Assets
72.789,01221.128.76741.89169.46
Asset Writedown
-55.27-146.59-321.16-491.98-3,478-316.08
Other Unusual Items
-----105.41
Pretax Income
11,9916,0036,90236,95623,08626,527
Income Tax Expense
-2,6312,1614,7568,7191,4946,944
Earnings From Continuing Operations
14,6223,8422,14628,23721,59119,583
Minority Interest in Earnings
3,4534,8443,417-798.76-1,208-1,712
Net Income
18,0768,6865,56327,43820,38317,870
Net Income to Common
18,0768,6865,56327,43820,38317,870
Net Income Growth
185.66%56.13%-79.72%34.61%14.06%-37.31%
Shares Outstanding (Basic)
282828282828
Shares Outstanding (Diluted)
282828282828
Shares Change
-0.30%0.14%-0.03%0.02%0.16%0.05%
EPS (Basic)
652.58313.37201.00991.07736.42646.68
EPS (Diluted)
652.58313.37201.00991.07736.42646.68
EPS Growth
186.53%55.91%-79.72%34.58%13.88%-37.37%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-3,597-38,442-40,6894,62610,79214,087
Free Cash Flow Per Share
-129.88-1386.89-1470.08167.09389.91509.78
Dividend Per Share
---180.000180.000180.000
Dividend Growth
---0%0%0%
Gross Margin
44.08%44.03%46.09%52.73%53.17%50.97%
Operating Margin
3.58%-0.05%2.89%5.17%8.79%7.68%
Profit Margin
3.52%1.75%1.20%7.60%5.99%6.10%
Free Cash Flow Margin
-0.70%-7.74%-8.75%1.28%3.17%4.81%
EBITDA
40,91621,72233,08032,56242,42434,591
EBITDA Margin
7.97%4.38%7.12%9.02%12.46%11.80%
D&A For EBITDA
22,52421,96519,66913,89612,50912,093
EBIT
18,392-243.2513,41118,66629,91522,499
EBIT Margin
3.58%-0.05%2.89%5.17%8.79%7.68%
Effective Tax Rate
-35.99%68.91%23.59%6.47%26.18%
Advertising Expenses
-45,05848,36841,14034,45529,889